This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Charles Schwab Corp. in 2017 - Teaching note
Siegel, R; Makinen, JTeaching Note SGSB-SM282TN-EStrategyBy almost any measure, Charles Schwab Corp. appeared to be killing it in 2017. The wealth management, banking, custody and brokerage firm’s stock was trading near its all-time high. It was posting unprecedented levels of new client accounts, net new client assets, revenues and profits and had a record $3.12 trillion in client assets under management. Schwab was taking customers and assets from old-line wire houses like Morgan Stanley, while fendi...Starting at €0.00
-
The Case for Professional Boards
Pozen, Robert C.Article HBS-R1012B-ELeadership and People ManagementWhen the world's largest financial institutions had to be rescued from insolvency in 2008, many experts laid the blame at the feet of corporate boards. But insufficient board oversight is a problem that had supposedly been solved in 2002. As the United States reeled from the blatant failures of corporate governance at Enron and WorldCom, Congress passed the famous Sarbanes-Oxley Act to prevent such failures from happening again. The new rules loo...Starting at €8.20
-
Charles Schwab Corp. in 2017
Siegel, R; Makinen, JCase SGSB-SM282-EStrategyBy almost any measure, Charles Schwab Corp. appeared to be killing it in 2017. The wealth management, banking, custody and brokerage firm’s stock was trading near its all-time high. It was posting unprecedented levels of new client accounts, net new client assets, revenues and profits and had a record $3.12 trillion in client assets under management. Schwab was taking customers and assets from old-line wire houses like Morgan Stanley, while fendi...Starting at €8.20
-
Ganeden Biotech, Inc.
Pozen, Robert C.; Winger, Dale; Ahlers, MatthewCase HBS-310073-ETo maximize their effectiveness, color cases should be printed in color. The CEO of Ganeden Biotech, a small firm with several viable probiotic products but limited resources, must decide what markets to invest in and what intellectual property strategies will best serve its immediate and longer term business interests.Starting at €8.20
-
Decoding CEO Pay*
Pozen, Robert C.; Kothari, S.P.Article HBS-R1704E-ELeadership and People ManagementEach year most public companies issue reports describing the pay packages of their CEOs. In them compensation committees attempt to explain the rationale behind the pay figures to the shareholders, who often must vote to approve them. The issue is, in their reports many committees adjust performance numbers in obscure and inappropriate ways that lead to overly generous CEO pay. And they do so using nonstandard criteria that are difficult for even...Starting at €8.20
-
Invitrogen/Life Technologies (B)
Burgelman, R; Siegel, R; Lee, RCase SGSB-SM209B-EStrategyOn June 12, 2008, Invitrogen and Applied Biosystems announced plans to merge. The combined company was to be renamed Life Technologies (NASDAQ: LIFE). Invitrogen offered to acquire Applied Biosystems for $6.7 billion in cash and stock. AB shareholders would receive $38 per share in cash and stock, representing a 17 percent premium over the share’s closing price on Wednesday, June 11, 2008.Starting at €5.74
-
Arm Yourself for the Coming Battle over Social Security (Spanish version)
Pozen, Robert C.Article HBS-R0211CEconomicsThe U.S. Social Security system is in deep trouble--and that's not just bad news for your friends and family. It's also bad news for your company. Unless the Social Security system is changed, by 2041 the system will be utterly insolvent. In the next decade, the very prospect of the rising deficit will mean serious pressure on recent tax cuts, higher long-term interest rates, increased pension-funding costs, and other punishing conditions for U.S...Starting at €8.20
-
Controlling Hot Money
Pozen, Robert C.Case HBS-311022-EFinanceThe manager of the Japan Equities Fund is faced with an increase in "hot money" moving quickly in and out of the Fund. This short term trading is an attempt to take advantage of the difference between the closing times of the Tokyo and New York Stock Exchanges. The CFO of the fund manager considers the various strategies available to limit such short term trading, which will be presented soon to the Fund's board of directors.Starting at €8.20
-
Flibe Energy: Pursuing a Safe, Affordable, and Sustainable Energy Future
Burgelman, R; Siegel, R; Nolan, SCase SGSB-SM208-EStrategyFlibe Energy is a startup in the nuclear power space seeking to find a safe way to enable nuclear energy using a technology previously dismissed by the US government since it could not be used for making material for nuclear weapons. The founders believe they have found a way to create safe, clean energy using a proven but forgotten technology. The challenges are steep, however, as proof of the technology will require hundreds of millions of doll...Starting at €8.20
-
Waste Management's Organic Growth Group
Burgelman, R; Siegel, R; Uribe, TCase SGSB-SM210-EStrategyIt was 2005 and David Steiner, CEO of Waste Management (WM), had just received a report from an internal advisory panel created some months before to assess the future of the waste management industry and propose how the company’s strategy should be adapted. The core of this report was the recommendation to create a special unit within the company, chartered with the central purpose of identifying ways to extract value from waste through new and ...Starting at €8.20